Replimune’s RP1+nivolumab melanoma BLA faces an FDA decision by Apr 10, 2026. The current cash runway extends to Q1'27. See more on REPL stock here.

Abstract: In this paper, an efficient approach for background modeling and subtraction is proposed. It's based on a novel spatial-color feature extraction operator ...

Coding jobs are thought to be under threat amid the AI wave, but it appears that code itself could end up becoming obsolete. Tesla and xAI CEO Elon Musk has endorsed a bold prediction about the future ...

Cboe Global Markets is in discussions with retail brokerages to relaunch “all-or-nothing” options contracts for individual investors that would vie with prediction markets. Cboe said the talks with ...

Astronomers have long faced a strange contradiction: most stars are born in pairs, and most stars have planets, so logically, planets orbiting two stars at once should be common. However, in reality, ...